Enrolled patients were initially treated with BDPFF TRIMARAN.

Trimaran trigger. Enrolled patients were initially treated with BDPFF TRIMARAN. Eligible patients were adults aged 18-75 years with uncontrolled asthma a history of one or more exacerbations in the previous year and previously treated with inhaled corticosteroid TRIMARAN. Eligible patients were adults aged 1875 years with uncontrolled asthma a history of one or more exacerbations in the previous year and previously treated with inhaled corticosteroid TRIMARAN.

Analyses of TRIMARAN and TRIGGER. High dose plus a long-acting β 2 agonist. TRIMARAN and TRIGGER are the first studies to assess the efficacy and safety of single-inhaler triple therapy in the management of asthma.

100 μg BDP and 6 μg FF. Furthermore the rate of moderate and severe exacerbations coprimary endpoint was met in TRIMARAN with a significant. Asthma Pharmacotherapy Long-acting β.

Anna Smith Chiesi Group has announced data from two Phase III studies TRIMARAN and TRIGGER the first studies to evaluate the relative efficacy and safety of extrafine formulation single-inhaler triple therapy compared with extrafine formulation inhaled corticosteroid ICS and long-acting β2 agonist LABA in adults with asthma. Analyses of TRIMARAN and TRIGGER. Determinants of response to inhaled extrafine triple therapy in asthma.

In a pre-specified pooled analysis BDPFFG also decreased the annualized rate of severe exacerbations versus BDPFF by 23 the rate of moderate exacerbations by 12 and moderate plus severe exacerbations by 14. The lung function predose FEV 1 coprimary endpoint was met in both studies with a slightly larger effect size in TRIGGER. After a run-in phase of 15 days patients were randomly assigned 11 to 52 weeks of triple therapy with medium dose beclomethasone 400μg formoterol glycopyronium BDPFFG or BDPFF in Trimaran and or were randomly assigned 221 to 52 weeks of high dose.

TRIMARAN and TRIGGER are two randomised parallel-group double-blind active-controlled studies. 200 μg BDP and 6 µg FF for 2 weeks then randomly assigned to treatment using an interactive response technology system with. 200 μg BDP and 6 μg FF for 2.